Caldeon

Caledon Bioscience is a clinical-stage biotechnology company focused on the discovery and development of small-molecule therapeutics targeting G-protein coupled receptors (GPCRs) to treat inflammatory, fibrotic, and metabolic diseases. The company was established as a spin-off following the acquisition and privatization of Liminal Biosciences by Thomvest Asset Management in 2023. Caledon's pipeline is anchored by a selective GPR84 antagonist currently entering clinical trials for the treatment of NASH and NAFLD. The company is also advancing an OXER1 antagonist for eosinophilic-driven conditions like asthma and a GPR40 agonist for metabolic disorders. Headquartered in Montreal with operations in Cambridge, UK, Caledon Bioscience leverages a legacy of GPCR expertise to address significant unmet needs in chronic disease management.